PubRank

M J Gallimore

Author PubWeight™ 31.63‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Studies on plasma antiplasmin activity using a new plasmin specific chromogenic tripeptide substrate. Thromb Res 1979 1.38
2 Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost 1992 1.37
3 Some aspects of fibrin clot lysis and its inhibition by human serum. Thromb Diath Haemorrh 1967 1.15
4 The influence of various plasma components on the lysis of dilute human blood clots. Thromb Diath Haemorrh 1969 1.05
5 Effect of diluents on blood clot lysis. J Clin Pathol 1967 0.92
6 Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000 0.92
7 Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 1982 0.91
8 Falls in plasma levels of prekallikrein, high molecular weight kininogen, and kallikrein inhibitors during lethal endotoxin shock in dogs. Thromb Res 1978 0.89
9 Modulation of morphological differentiation of human neuroepithelial cells by serine proteases: independence from blood coagulation. EMBO J 1989 0.89
10 Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001 0.87
11 Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma. Thromb Res 1982 0.85
12 Serum inhibitors in fibrinolysis. Br J Haematol 1975 0.85
13 Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost 1999 0.85
14 Studies on plasma inhibitors of plasma kallikrein using chromogenic peptide substrate assays. Thromb Res 1979 0.84
15 The measurement of fibrinolysis in the rat. Thromb Diath Haemorrh 1971 0.83
16 FXII. Blut 1990 0.83
17 The origin of fibrin breakdown products and the interpretation of their appearance in the circulation. J Clin Pathol 1972 0.82
18 The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb Res 1978 0.81
19 Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock. Adv Shock Res 1980 0.81
20 FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery. Immunopharmacology 1999 0.79
21 Determination of plasma aprotinin levels by functional and immunologic assays. Blood Coagul Fibrinolysis 2001 0.79
22 Activation of human plasma prekallikrein: influence of activators, activation time and temperature and inhibitors. Thromb Res 1978 0.78
23 Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model. Immunopharmacology 1996 0.78
24 Inhibition of the amidolytic activity of urokinase by human plasma. Thromb Res 1980 0.78
25 Recurrent abortion-antibodies to factor XII or a decrease in factor XII levels? Fertil Steril 2001 0.78
26 Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma. Adv Exp Med Biol 1986 0.77
27 Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock. Thromb Res 1980 0.77
28 Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992 0.77
29 Antibodies to factor XII are distinct from antibodies to prothrombin in patients with the anti-phospholipid syndrome. Thromb Haemost 2002 0.77
30 The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome. J Thromb Haemost 2005 0.76
31 More on: Discovery of alpha2-plasmin inhibitor and its congenital deficiency. J Thromb Haemost 2006 0.76
32 Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. Adv Exp Med Biol 1986 0.76
33 Veno-venous bypass in liver transplantation: heparin-coated perfusion circuits reduce the activation of humoral defense systems in an in vitro model. Perfusion 2001 0.76
34 Antiplasmin concentrations after surgery. Br Med J 1979 0.75
35 Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost 1993 0.75
36 Factor XII determinations and lupus anticoagulants. Blood Coagul Fibrinolysis 1997 0.75
37 More on: Pathogenic antibodies to coagulation factors. Part II: Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, protein C and von Willebrand factor. J Thromb Haemost 2006 0.75
38 Chromogenic peptide substrate assays for determining components of the plasma kallikrein system. Scand J Clin Lab Invest Suppl 1985 0.75
39 Studies on components of the plasma kallikrein system as a risk factor in diabetics undergoing cardiopulmonary bypass. Agents Actions Suppl 1992 0.75
40 Pseudo factor XII deficiency and phospholipid antibodies. Thromb Haemost 1996 0.75
41 Studies on shock during extracorporeal circulation during aorto-coronary bypass operations. Prog Clin Biol Res 1987 0.75
42 Inter-alpha-antiplasmin: its distinction from antiactivator. Thromb Res 1978 0.75
43 Alterations of plasmin activity, plasminogen levels and activity of antiplasmins during endotoxin shock in dogs. Haemostasis 1978 0.75
44 Prekallikrein activator. Thromb Haemost 1984 0.75
45 Studies on the inhibition of plasma kallikrein, C1-esterase and beta-FXIIa in the presence and the absence of heparins. Adv Exp Med Biol 1989 0.75
46 Changes in plasma levels of prekallikrein, kallikrein, high molecular weight kininogen and kallikrein inhibitors during lethal endotoxin shock in dogs. Haemostasis 1978 0.75
47 Levels of IgA, IgM, IgG and complement components during extracorporal circulation. Adv Exp Med Biol 1986 0.75
48 Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model. Blood Coagul Fibrinolysis 1994 0.75
49 Changes in antiplasmin and plasmin activities during extreme hemodilution and open heart surgery in dogs. Eur Surg Res 1979 0.75
50 Changes in the kallikrein-kinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol 1989 0.75
51 Studies on components of the plasma kallikrein and complement systems in plasma and serum samples from normal individuals and patients with hereditary angioedema. Adv Exp Med Biol 1983 0.75
52 Parameters of the kallikrein-kinin, coagulation and fibrinolytic systems as early indicators of kidney transplant rejection. Nephron 1988 0.75
53 An automated chromogenic peptide substrate assay for coagulation factor XII. Blood Coagul Fibrinolysis 1998 0.75
54 Aprotinin in therapeutic doses inhibits chromogenic peptide substrate assays for protein C. Thromb Res 1994 0.75
55 Plasma proteolytic activity in liver transplant rejection. Transpl Int 1999 0.75
56 Studies on synthetic peptide substrates for F XII enzymes. Adv Exp Med Biol 1986 0.75
57 Chromogenic substrate assays for studying components of the plasma kallikrein system in health and disease. Adv Exp Med Biol 1983 0.75
58 Changes in components of the KK-system after recirculation and the addition of plasma kallikrein. Adv Exp Med Biol 1989 0.75
59 Effect of high and low molecular weight heparin preparations on chromogenic substrate assays for components of the kallikrein-kinin system. Adv Exp Med Biol 1986 0.75
60 Inhibition of beta-FXIIa in plasma of volunteers and polytraumatized patients. Prog Clin Biol Res 1987 0.75
61 The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993 0.75
62 Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model. Immunopharmacology 1996 0.75
63 Further evidence for the presence of two plasma inhibitors of fibrinolysis distinct from alpha2-macroglobulin. Thromb Res 1977 0.75
64 Studies on Hageman factor, plasma prekallikrein, kallikrein "like" activity and kallikrein inhibition in plasma samples from normal subjects and clinical material. Adv Exp Med Biol 1983 0.75
65 Factor XII levels in patients after abdominal surgery. Adv Exp Med Biol 1989 0.75